TY  - JOUR
T1  - Thymoquinone Prevents Doxorubicin-induced Hepatic-injury by Mitigating the Impairment of Mitochondrial Respiration and Electron Transport
A1  - Batoul Madani
A1  - Abdulhadi Burzangi
A1  - Huda Alkreathy
A1  - Shahid Karim
A1  - Rasheed Ahemad Shaik
A1  - Lateef Khan
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2022
VL  - 11
IS  - 3
DO  - 10.51847/0hqldEZBtj
SP  - 89
EP  - 97
N2  - Doxorubicin (DXR) is an anthracycline antibiotic that is commonly used in cancer treatment. The purpose of this study was to see if Thymoquinone (THY) could reduce the hepatotoxic effects of doxorubicin. All animals were divided into four groups: control (Phosphate buffer i.p. 0.5mlkg-1/day), THY (10mgkg-1/i.p/daily), doxorubicin (20mgkg-1/i.p/single dose), THY (10mgkg-1/i.p/daily) + DOX(20mgkg-1/i.p/single dose on Day 7). Changes in hepatic enzymes in serum ALT, AST, and GGT, as well as tests for free radical metabolism enzymes such as Cu, Zn-SOD, CAT, and MDA were carried out in all animals that received treatments. In addition, the inflammatory markers IL-6, Nf-kB, and TNF-alpha were measured in liver tissue homogenate. Caspase, an apoptosis marker, was also measured. The liver enzymes were significantly elevated in DOX treated rats as compared to all treated groups. Thymoquinone pretreatment significantly reduced the level of hepatic enzymes as compared to DOX. Comparison of the DOX-treated group to the control group showed that SOD and catalase activities rose significantly. In the DOX-treated group, malondialdehyde levels were higher than in the control and all-treatment groups, respectively (P
UR  - https://ijpras.com/article/thymoquinone-prevents-doxorubicin-induced-hepatic-injury-by-mitigating-the-impairment-of-mitochondri-hu46fbw0rkwukgg
ER  -